Literature DB >> 1385307

The hypervariable DXS255 locus contains a LINE-1 repetitive element with a CpG island that is extensively methylated only on the active X chromosome.

R W Hendriks1, H Hinds, Z Y Chen, I W Craig.   

Abstract

The DXS255 locus at Xp11.22 is highly polymorphic due to a 26-bp variable number of tandem repeats (VNTR) motif. In previous studies, one of the MspI sites flanking the VNTR manifested a correlation between methylation and X chromosome inactivation. Here we show, by DNA sequence analysis, that this MspI site is located within the CpG island at the 5' end of a LINE-1 element, which is 2.5 kb from the VNTR. The methylation status of the CpG island was assessed in Southern blotting experiments using the methylation-sensitive enzymes HpaII, HhaI, and BssHII. All these sites were completely methylated on active X chromosomes, consistent with previously reported findings of full methylation of LINE-1 elements throughout the genome. However, on inactive X chromosomes these sites were predominantly unmethylated, although patterns were found to be heterogeneous. The results suggest that LINE-1 elements on the inactive X chromosome are not suppressed by full methylation of their CpG islands. The differential methylation of the DXS255 CpG island provides the basis for a highly informative X inactivation analysis system.

Mesh:

Substances:

Year:  1992        PMID: 1385307     DOI: 10.1016/s0888-7543(05)80157-0

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  11 in total

1.  X-chromosome methylation ratios as indicators of chromosomal activity: evidence of intraindividual divergencies among tissues of different embryonal origin.

Authors:  J Azofeifa; R Waldherr; M Cremer
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

2.  X-inactivation pattern in carriers of X-linked retinitis pigmentosa: a valuable means of prognostic evaluation?

Authors:  U Friedrich; M Warburg; A L Jørgensen
Journal:  Hum Genet       Date:  1993-10       Impact factor: 4.132

3.  Is skewed X inactivation responsible for symptoms in female carriers for adrenoleucodystrophy?

Authors:  E Watkiss; T Webb; S Bundey
Journal:  J Med Genet       Date:  1993-08       Impact factor: 6.318

4.  X chromosome inactivation in 30 girls with Rett syndrome: analysis using the probe.

Authors:  P Camus; N Abbadi; M C Perrier; M Chéry; S Gilgenkrantz
Journal:  Hum Genet       Date:  1996-02       Impact factor: 4.132

5.  X inactivation patterns in female monozygotic twins and their families.

Authors:  E Watkiss; T Webb; G Rysiecki; N Girdler; E Hewett; S Bundey
Journal:  J Med Genet       Date:  1994-10       Impact factor: 6.318

6.  X chromosome inactivation and the diagnosis of X linked disease in females.

Authors:  R M Brown; G K Brown
Journal:  J Med Genet       Date:  1993-03       Impact factor: 6.318

Review 7.  Pyridoxine-refractory congenital sideroblastic anaemia with evidence for autosomal inheritance: exclusion of linkage to ALAS2 at Xp11.21 by polymorphism analysis.

Authors:  P E Jardine; P D Cotter; S A Johnson; E J Fitzsimons; L Tyfield; P W Lunt; D F Bishop
Journal:  J Med Genet       Date:  1994-03       Impact factor: 6.318

8.  Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia.

Authors:  A Arnold; M F Brown; P Ureña; R D Gaz; E Sarfati; T B Drüeke
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

9.  X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes.

Authors:  J Azofeifa; T Voit; C Hübner; M Cremer
Journal:  Hum Genet       Date:  1995-08       Impact factor: 4.132

10.  Common methylation characteristics of sex chromosomes in somatic and germ cells from mouse, lemur and human.

Authors:  J Bernardino; M Lombard; A Niveleau; B Dutrillaux
Journal:  Chromosome Res       Date:  2000       Impact factor: 4.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.